Obsidian Therapeutics, Inc. (NasdaqCM: OBX)
Health Care · Biotechnology · US
$12.21
+1.16% today · +78.5% 1Y
Obsidian Therapeutics, Inc. (NasdaqCM: OBX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $754.25M and employs 87 people.
Over the last twelve months the share price has gained 78.5%, trading between 5.70 and 49.97.
Tweenvest scores Obsidian Therapeutics, Inc. across four factors: quality 44/100, value 57/100. Its strongest factor is value.
OBX price history
Key figures
- Market cap
- $754.25M
- Revenue (TTM)
- —
- P/E
- -9.08
- EPS
- -2,056.18
- Dividend yield
- —
- Beta (5Y)
- 3.06
- 52-week high
- $49.97
- 52-week low
- $5.70
- Avg volume (3M)
- —
- Shares outstanding
- 61.77M
- Employees
- 87
- Next earnings
- —
About Obsidian Therapeutics, Inc.
A clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies for the treatment of patients with solid tumors. Its proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs.
- ISIN
- US67448A1060
- Founded
- 2015
- Listed since
- Aug 4, 2026
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Ardelyx, Inc.NasdaqGM: ARDX | $784.28M | $3.12 | -1.89% |
| ORIC Pharmaceuticals, Inc.NasdaqGS: ORIC | $779.47M | $7.52 | -4.33% |
| Monte Rosa Therapeutics, Inc.NasdaqGS: GLUE | $775.03M | $9.07 | 0.00% |
| Kolon TissueGene, Inc.KOSDAQ: A950160 | $772.30M | ₩12,150.00 | -3.19% |
| Inventiva S.A.ENXTPA: IVA | $753.92M | €2.91 | +0.69% |
| Ingenia Therapeutics Inc.KOSDAQ: A950260 | $752.71M | ₩20,350.00 | +1.24% |
| Nanjing Leads Biolabs Co., Ltd.SEHK: 9887 | $748.03M | HK$30.08 | -1.96% |
| Beijing SL Pharmaceutical Co., Ltd.SZSE: 002038 | $745.83M | CN¥4.84 | -2.22% |